Detalles de la búsqueda
1.
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
J Urol
; 209(5): 890-900, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37026631
3.
Development and validation of a 32-gene prognostic index for prostate cancer progression.
Proc Natl Acad Sci U S A
; 110(15): 6121-6, 2013 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-23533275
4.
The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: A Phase 1b Study.
Eur Urol Open Sci
; 62: 8-15, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38585206
5.
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Urol Oncol
; 40(7): 344.e1-344.e9, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35431132
Resultados
1 -
5
de 5
1
Próxima >
>>